These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37583815)

  • 21. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
    Quintás-Cardama A
    Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Hexahydrofuro[3,2-
    Li S; Si H; Song X; Lei C; He X; Wang J; Liu Y; Zhou Y; Song JG; Peng L; Tang X; Chan S; Ren X; Tu Z; Li Z; Wang Z; Zhang Z; Ding K
    J Med Chem; 2022 Aug; 65(15):10674-10690. PubMed ID: 35860875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
    Meyer DM; Jesson MI; Li X; Elrick MM; Funckes-Shippy CL; Warner JD; Gross CJ; Dowty ME; Ramaiah SK; Hirsch JL; Saabye MJ; Barks JL; Kishore N; Morris DL
    J Inflamm (Lond); 2010 Aug; 7():41. PubMed ID: 20701804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
    Nair PC; Piehler J; Tvorogov D; Ross DM; Lopez AF; Gotlib J; Thomas D
    Blood Cancer Discov; 2023 Sep; 4(5):352-364. PubMed ID: 37498362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.
    Nakaya Y; Shide K; Niwa T; Homan J; Sugahara S; Horio T; Kuramoto K; Kotera T; Shibayama H; Hori K; Naito H; Shimoda K
    Blood Cancer J; 2011 Jul; 1(7):e29. PubMed ID: 22829185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.
    Park E; Park S; Lee SJ; Jeong D; Jin H; Moon H; Cha B; Kim D; Ma S; Seo W; Han SH; Lee YS; Kang S
    J Med Chem; 2023 Dec; 66(23):16342-16363. PubMed ID: 38031930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
    Baffert F; Régnier CH; De Pover A; Pissot-Soldermann C; Tavares GA; Blasco F; Brueggen J; Chène P; Drueckes P; Erdmann D; Furet P; Gerspacher M; Lang M; Ledieu D; Nolan L; Ruetz S; Trappe J; Vangrevelinghe E; Wartmann M; Wyder L; Hofmann F; Radimerski T
    Mol Cancer Ther; 2010 Jul; 9(7):1945-55. PubMed ID: 20587663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
    Cui X; Teng Y; Hu Y; Li Q; Pei H; Yang Z
    Int Immunopharmacol; 2024 Jan; 126():111238. PubMed ID: 37988912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
    Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
    J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions.
    Liu X; Wang B; Liu Y; Yu Y; Wan Y; Wu J; Wang Y
    Mol Divers; 2023 Nov; ():. PubMed ID: 38006563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between JAK2(V617F) mutation and dermatomyositis-a case report and literature review.
    Xu Q; Jin X; Jiang Y; Dang X; Han Y
    Clin Rheumatol; 2021 Mar; 40(3):1147-1157. PubMed ID: 32676918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
    Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
    J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
    Shide K; Kameda T; Markovtsov V; Shimoda HK; Tonkin E; Fang S; Liu C; Gelman M; Lang W; Romero J; McLaughlin J; Bhamidipati S; Clough J; Low C; Reitsma A; Siu S; Pine P; Park G; Torneros A; Duan M; Singh R; Payan DG; Matsunaga T; Hitoshi Y; Shimoda K
    Blood; 2011 Jun; 117(25):6866-75. PubMed ID: 21531978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors.
    Álvarez-Reguera C; Prieto-Peña D; Herrero-Morant A; Sánchez-Bilbao L; Batlle-López A; Fernández-Luis S; Paz-Gandiaga N; Blanco R
    Eur J Intern Med; 2024 May; 123():102-106. PubMed ID: 38044168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.